The interaction between the internal clock and antidepressant efficacy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Sleep disturbances are often associated with depression and mood disorders, and certain manipulations of the sleep-wake cycle are effective as therapeutic interventions in the treatment of depression. Dysregulated circadian rhythms are thereby considered as causal. Circadian rhythms in mammals are mainly regulated by a core biological clock, located in the hypothalamic suprachiasmatic nucleus; its pacemaker activity is regulated by light and nonphotic modulatory pathways, and the driving mechanisms are serotonergic input from the raphe and the hormone melatonin originating from the pineal gland. In line, the concentration of brain serotonin and the levels of 5-HT2C receptors are high and highly expressed there. Agomelatine, a novel antidepressant drug with proven clinical efficacy in major depressive disorder, has a unique mechanism of action; it acts as an agonist at melatonergic MT1 and MT2 receptors and as an antagonist at 5-HT2C receptors. In animals, agomelatine was shown to increase noradrenaline and dopamine (but not serotonin) in the frontal cortex, to resynchronize the sleep-wake cycle in models with disrupted circadian rhythms, and to exhibit a clear antidepressant effect in various animal models of depression. On the basis of the functional relationship between melatonergic and serotonergic signaling in the suprachiasmatic nucleus, and given agomelatine's affinity at melatonergic and 5-HT2C receptors, the therapeutic efficacy of the drug may be due to the potential synergy of its action at these different receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Souêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396 · cited 2×
“scale for depression score in depressed patients (Souetre et al., 1989).”
BackgroundHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
Self-citation
Cited by
Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., & Olcese, J. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002832 · Cited by 621
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
The circadian basis of mood disorders: Recent developments and treatment implications
Monteleone, P., & Maj, M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.007 · Cited by 185
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Bartlang, M. S., Neumann, I. D., Slattery, D. A., Uschold-Schmidt, N., Kraus, D., Helfrich-Förster, C., & Reber, S. O. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0267 · Cited by 49
Metadata
- Authors
- Racagni, G., Riva, M. A., & Popoli, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-10
- Volume
- 22
- Issue
- Supplement 2
- Pages
- S9-S14
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1987755278
- Cited by
- 49
- References
- 2
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The interaction between the internal clock and antidepressant efficacy. https://app.cochat.ai/papers/10.1097/01.yic.0000277957.75852.c7
- The paper
- Racagni, G., Riva, M. A., & Popoli, M. (2007). The interaction between the internal clock and antidepressant efficacy. International Clinical Psychopharmacology. https://doi.org/10.1097/01.yic.0000277957.75852.c7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.